Table 2 Clinical characteristics of TLE patients and post-mortem controls

Gender

Age (years)

PMI (h)

Resection side

Male

62

20

Right

Male

66

39

Right

Male

76

14

Left

Male

80

22

Right

Male

66

14

Right

Male

61

19

Right

Female

84

13

Right

Female

64

42

Right

Female

85

17

Right

Male

83

12

Right

Gender

Age at surgery (years)

Age of onset (years)

Duration

Pathology

Antiepileptic drugs

Male

58

53

5

HS^-

VPA, CBZ, LTG, LEV

Female

51

24

27

HS^-

LEV, CBZ, LTG

Male

37

31

6

HS^-

LEV, VPA, CBZ, LTG

Female

60

17

43

HS^-

LTG, CBZ, LEV, CLB

Female

40

16

24

HS^-

PHT, DZP, OXC, CLZ

Male

20

N/A

N/A

HS^-

N/A

Male

47

31

16

HS^-

CLB, OXC, LEV

Male

29

20

9

HS^-

OXC, LEV

Female

39

30

9

HS^-

LTG, CBZ

Female

21

20

1

HS^-

LEV, LAC

Female

59

7

52

HS^-

CBZ, CLB

Female

41

27

14

HS^-

LEV, CBZ, CLB

Female

21

1

20

HS^-

CLE, LEV

Male

19

8

8

HS^-

CBZ, CLZ, LEV

Female

39

4

35

HS⁺

DZP, CLB, LEV, OXC

Male

63

2.5

60.5

HS⁺

CBZ, CLB, PHT, CLZ

Female

43

3

40

HS⁺

LTG, CLZ, DZP, LEV, CLB

Female

58

54

4

HS⁺

LTG, LEV, OXC, CBZ

Male

47

3

44

HS⁺

LEV, PHT

Male

54

17

37

HS⁺

FLU, LTG, MET, ZOP

Male

28

4

24

HS⁺

CBZ, LTG

Female

23

19

4

HS⁺

MDZ

Female

47

11

36

HS⁺

LTG, CLB, TMP, VPA

Male

55

10

45

HS⁺

MDZ, CBZ, CLB, LEV

Male

48

30

18

HS⁺FS⁺

LTG, CLB, TPM

Female

23

6

16

HS⁺FS⁺

LEV, LTG, CLB

Female

59

N/A

N/A

HS⁺FS⁺

OXC, CLB, LEV

Female

50

47

3

HS⁺FS⁺

OXC, LEV, CLB

Female

23

1

22

HS⁺FS⁺

LTG, TPM, CLB, OXC

Male

60

2

58

HS⁺FS⁺

CBZ, VPA, LTG, DZP

Male

36

9

27

HS⁺FS⁺

LEV, VPA, OXC

Female

41

4

37

HS⁺FS⁺

CLZ, CBZ

Female

20

1

19

HS⁺FS⁺

MDZ, LEV, TMP

Female

43

28

15

HS⁺FS⁺

LEV, LTG, CLB

Male

42

8

34

HS⁺FS⁺

LTG, CLB

Male

33

0

33

HS⁺FS⁺

CBZ, CLB, MDZ

Female

41

20

21

HS⁺FS⁺

LEV, LTG, CLB